Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus bevacizumab for biomarker-selected recurrent ovarian cancer
ChiCTR2400093580Phase 2Not yet recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and bevacizumab in ovarian cancer and High-Grade Serous Ovarian Cancer (HGSOC), sponsored by Obstetrics and Gynecology Hospital of Fudan University. Primary endpoint: Objective response rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
camrelizumabbevacizumab
03
Conditions
ovarian cancerHigh-Grade Serous Ovarian Cancer (HGSOC)
Beyond the preview
Go deeper on ChiCTR2400093580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093580.